Advertisement

The effects of chronic naltrexone treatment in young autistic children: A double-blind placebo-controlled crossover study

      This paper is only available as a PDF. To read, Please Download here.
      In a double-blind placebo-controlled crossover trial 23 autistic children, aged 3–7 years, were treated with a mean daily dosage of 1 mg/kg naltrexone for 4 weeks. Drug effects were monitored with behavior checklists rated by parents and teachers, and ethological playroom observations. On average, parents' checklists and playroom data could not differentiate between naltrexone treatment and placebo treatment; however, teachers significantly favored naltrexone treatment. They reported a decrease in hyperactivity and irritability. No effects of naltrexone on social and stereotypic behavior could be demonstrated.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aman MG
        • Singh NN
        • Stewart AW
        • Field CJ
        The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects.
        Am J Ment Defic. 1985; 89: 485-491
      1. (DSM-III-R)
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders.
        3rd ed rev. American Psychiatric Press, Stuttgart, New York1987
        • Asleson GS
        • Herman BH
        • Borghese IF
        • Allen RP
        • Arthur-Smith A
        Effects of acute naltrexone on locomotor activity in autistic children.
        Soc Neurosci Abstr. 1991; 17: 1346
        • Berridge CW
        • Arnsten AFT
        • Foote SL
        Noradrenergic modulation of cognitive function: Clinical implications of anatomical, electrophysiological and behavioural studies in animal models.
        Psychol Med. 1993; 23: 557-564
        • Borbely AA
        New techniques for the analysis of the human sleep-wake cycle.
        Brain Dev. 1986; 8: 482-488
        • Borghese IF
        • Herman BH
        • Asleson GS
        • Chantoor I
        • Benoit MB
        • Papero P
        • McNulty G
        Effects of acutely administered naltrexone on social behavior of autistic children.
        Soc Neurosci Abstr. 1991; 17: 1252
        • Borghese IF
        • Herman BH
        • Anselmi LS
        • Asleson G
        • Lukens E
        • Benoit MB
        • Chantoor I
        • Papero P
        Effects of acutely and chronically administered naltrexone on social behavior and language of children with autism.
        Soc Neurosci Abstr. 1993; 19: 1785
        • Buitelaar JK
        Endogenous opioids and their putative role in disturbances of social behavior, in particular in autism.
        in: Macher JP Crocq MA The Bio-Clinical Interface, Proceedings of the IXth Conference, Rouffach, France, September 23–26, 1992 Elsevier Science Publishers B.V., Washington, DC1993
        • Buitelaar JK
        • Van Engeland H
        • Van Ree JM
        • De Wied D
        Behavioral effects of ORG 2766, a synthetic analog of the adrenocorticotrophic hormone (4–9) in 14 outpatient autistic children.
        J Autism Dev Disord. 1990; 20: 467-478
        • Buitelaar JK
        • Van Engeland H
        • De Kogel CH
        • De Vries H
        • Van Hooff J
        • Van Ree J
        The adrenocorticotrophic hormone (4–9) analog ORG-2766 in autistic children: Effects on the organization of behavior.
        Biol Psychiatry. 1992; 31: 1119-1129
        • Buitelaar JK
        • Van Engeland H
        • De Kogel CH
        • De Vries H
        • Van Hooff J
        • Van Ree JK
        The adrenocorticotrophic hormone (4–9) analog ORG-2766 benefits autistic children—Report on a second controlled clinical trial.
        J Am Acad Child Adolesc Psychiatry. 1992; 31: 1149-1156
        • Campbell M
        • Adams P
        • Small AM
        • McVeigh Tesch L
        • Curren EL
        Naltrexone in infantile autism.
        Psychopharmacol Bull. 1988; 24: 135-139
        • Campbell M
        • Overall JE
        • Small AM
        • Sokol MS
        • Spencer EK
        • Adams P
        • Foltz RL
        • Monti KM
        • Perry R
        • Nobler M
        • Roberts E
        Naltrexone in autistic children: An acute open dose range tolerance trial.
        J Am Acad Child Adolesc Psychiatry. 1989; 28: 200-206
        • Campbell M
        • Anderson LT
        • Small AM
        • Locascio JJ
        • Lynch NS
        • Choroco MC
        Naltrexone in autistic children: A double-blind and placebo-controlled study.
        Psychopharmacol Bull. 1990; 26: 130-135
        • Campbell M
        • Anderson LT
        • Small AM
        • Adams P
        • Gonzalez NM
        • Ernst M
        Naltrexone in autistic children: Behavioral symptoms and attentional learning.
        J Am Acad Child Adolesc Psychiatry. 1993; 32: 1283-1291
        • Dokla CPJ
        Naloxone reduces social locomotor activity in rats.
        Pharmacol Biochem Behav. 1992; 43: 1183-1193
        • Gillberg C
        • Terenius L
        • Hagberg B
        • Witt-Engerström I
        • Eriksson I
        CSF beta-endorphins in childhood neuropsychiatric disorders.
        Brain Dev. 1990; 12: 88-92
        • Herman BH
        • Hammock MK
        • Arthur-Smith A
        • Egan J
        • Chatoor I
        • Zelnik N
        • Corradine M
        • Appelgate K
        • Boeckx RL
        • Sharp SD
        Role of opioid peptides in autism: Effects of acute administration of naltrexone.
        Soc Neurosci Abstr. 1986; 12: 1172
        • Herman BH
        • Asleson GS
        • Borghese IF
        • Chantoor I
        • Benoit MB
        • Powell A
        • Papero P
        • Allen RP
        • McNulty G
        Acute natrexone in autism: Selective decreases in hyperactivity.
        in: Scientific Proceedings, 38th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. AACAP, Amsterdam1991: 52
        • Herman BH
        • Asleson G
        • Lukens E
        • Borghese I
        • Anselmi L
        • Allen RP
        • Benoit MB
        • Chatoor I
        • Papero P
        Acute and chronic naltrexone decreases the hyperactivity of autism.
        Soc Neurosci Abstr. 1993; 19: 1785
        • Jacobson NS
        • Truax P
        Clinical significance: A statistical approach to defining meaningful change in psychotherapy research.
        J Consult Clin Psychology. 1991; 59: 12-19
        • Katz RJ
        Endorphins, exploration and activity.
        in: Rodgers RJ Cooper SJ Endorphins, Opiates and Behavioural Processes. John Wiley & Sons Ltd., Washington DC1988: 249-267
        • Kolmen BK
        • Feldman HM
        • Handen BL
        • Janosky JE
        Naltrexone in young autistic children: A double-blind, placebo-controlled crossover study.
        J Am Acad Child Adolesc Psychiatry. 1995; 34: 223-231
        • Leboyer M
        • Bouvard MP
        • Dugas M
        Effects of naltrexone on infantile autism.
        Lancet. 1988; 26: 715
        • Leboyer M
        • Bouvard MP
        • Lensing P
        • Launay J-M
        • Tabuteau F
        • Arnaud P
        • Waller D
        • Plumet M-H
        • Recasens C
        • Kerdelhue B
        • Dugas M
        • Panksepp J
        Opioid excess hypothesis of autism: A double-blind study of naltrexone.
        Brain Dysfunction. 1990; 3: 285-298
        • Leboyer M
        • Bouvard MP
        • Launay J
        • Tableau F
        • Waller D
        • Dugas M
        • Kerdelhue B
        • Lensing P
        • Panksepp J
        Brief report: A double-blind study of naltrexone in infantile autism.
        J Autism Dev Disord. 1992; 22: 309-319
        • Leboyer M
        • Bouvard MP
        • Recasens C
        • Philippe A
        • Guilloud-Bataille M
        • Bondoux D
        • Tabuteau F
        • Dugas M
        • Panksepp J
        • Launay J
        Difference between plasma N- and C-terminally directed β-endorphin immunoreactivity in infantile autism.
        Am J Psychiatry. 1994; 151: 1797-1801
        • Marshburn EC
        • Aman MG
        Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation.
        J Autism Dev Disord. 1992; 22: 357-373
        • Matson JL
        • Rotatori AF
        • Helsel WJ
        Special Feature: Development of a rating scale to measure social skills in children: The Matson Evaluation of Social Skills with Youngsters (MESSY).
        Psychopharmacol Bull. 1985; 21: 855-868
        • National Institute of Mental Health
        Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research.
        Psychopharmacol Bull. 1985; 21: 839-842
        • Noldus LPJJ
        The observer: A software system for collection and analysis of observational data.
        Behav Res Methods Instruments & Computers. 1991; 23: 415-429
        • Panksepp J
        A neurochemical theory of autism.
        Trends Neurosci. 1979; 2: 174-177
        • Panksepp J
        • Sahley TL
        Possible brain opioid involvement in disrupted social intent and language development of autism.
        in: Schopler E Mesibov GB Neurobiological Issues in Autism. Plenum Press, Chichester1987: 357-372
        • Panksepp J
        • Leboyer M
        • Bouvard MP
        • Lensing P
        Naltrexone in infantile autism—response.
        J Autism Dev Disord. 1994; 24: 238-239
        • Ross DL
        • Klykylo WM
        • Hitzemann R
        Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism.
        Pediatr Neurol. 1987; 3: 83-86
        • Sandman CA
        • Barron JL
        • Chicz-DeMet A
        • DeMet EM
        Brief report: Plasma β-endorphin and cortisol levels in autistic patients.
        J Autism Dev Disord. 1991; 21: 83-87
        • Schopler E
        • Reichler RJ
        • DeVellis RF
        • Daly K
        Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS).
        J Autism Dev Disord. 1980; 10: 91-103
        • Strahlendorf HK
        • Strahlendorf JC
        • Barnes CD
        Endorphin-mediated inhibition of locus coeruleus neurons.
        Brain Res. 1980; 191: 284-288
        • Walters AS
        • Barrett RP
        • Feinstein C
        • Mercurio A
        • Hole WT
        A case report of naltrexone treatment of self-injury and social withdrawal in autism.
        J Autism Dev Disord. 1990; 20: 169-176
        • Weizman R
        • Gil-Ad I
        • Dick J
        • Tyano S
        • Szekely GA
        • Laron Z
        Low plasma immunoreactive β-endorphin levels in autism.
        J Am Acad Child Adolesc Psychiatry. 1988; 27: 430-433
      2. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, Van Engeland H (in press): A placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res.

        • Wing L
        • Gould J
        Severe impairments of social interaction and associated abnormalities in children: Epidemiology and classification.
        J Autism Dev Disord. 1979; 9: 11-29